MDT

88.42

-0.26%↓

VEEV

282.22

-0.26%↓

A

120.83

+0.49%↑

WBA

11.48

-0.09%↓

HQY

101.21

-1.67%↓

MDT

88.42

-0.26%↓

VEEV

282.22

-0.26%↓

A

120.83

+0.49%↑

WBA

11.48

-0.09%↓

HQY

101.21

-1.67%↓

MDT

88.42

-0.26%↓

VEEV

282.22

-0.26%↓

A

120.83

+0.49%↑

WBA

11.48

-0.09%↓

HQY

101.21

-1.67%↓

MDT

88.42

-0.26%↓

VEEV

282.22

-0.26%↓

A

120.83

+0.49%↑

WBA

11.48

-0.09%↓

HQY

101.21

-1.67%↓

MDT

88.42

-0.26%↓

VEEV

282.22

-0.26%↓

A

120.83

+0.49%↑

WBA

11.48

-0.09%↓

HQY

101.21

-1.67%↓

Search

Krystal Biotech Inc

Geschlossen

BrancheGesundheitswesen

141.21 1.61

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

137.16

Max

143

Schlüsselkennzahlen

By Trading Economics

Einkommen

-9.7M

36M

Verkäufe

-3M

88M

KGV

Branchendurchschnitt

32.964

40.527

EPS

1.196

Gewinnspanne

40.521

Angestellte

275

EBITDA

-5.1M

38M

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+40.55% upside

Dividenden

By Dow Jones

Nächstes Ergebnis

4. Aug. 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-829M

4B

Vorheriger Eröffnungskurs

139.6

Vorheriger Schlusskurs

141.21

Nachrichtenstimmung

By Acuity

50%

50%

163 / 380 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Very Strong Bearish Evidence

Krystal Biotech Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

2. Juli 2025, 17:03 UTC

Wichtige Markttreiber

Furniture Companies Rise on U.S. Trade Deal With Vietnam

2. Juli 2025, 15:18 UTC

Wichtige Markttreiber

Mogo Shares Rally After Embrace of Bitcoin Into Holdings, Operations

2. Juli 2025, 23:45 UTC

Market Talk

Global Equities Roundup: Market Talk

2. Juli 2025, 23:45 UTC

Market Talk

Nikkei May Trade Rangebound Amid U.S. Tariff Uncertainty -- Market Talk

2. Juli 2025, 23:40 UTC

Market Talk

Gold Edges Lower Amid Hopes for More Trade Deals -- Market Talk

2. Juli 2025, 21:01 UTC

Akquisitionen, Fusionen, Übernahmen

AT&T Completes Sale of Entire Remaining 70% Stake in DIRECTV to TPG >T

2. Juli 2025, 21:01 UTC

Akquisitionen, Fusionen, Übernahmen

AT&T and TPG Close DIRECTV Transaction

2. Juli 2025, 20:26 UTC

Ergebnisse

Rivian Stock Drops on Sales Decline. The Stakes Are High for the Rest of 2025. -- Barrons.com

2. Juli 2025, 20:22 UTC

Market Talk

Gold Rises Following Weak ADP Payroll Reading -- Market Talk

2. Juli 2025, 20:13 UTC

Market Talk

Oil Price Expectations Stable in Dallas Fed Survey -- Market Talk

2. Juli 2025, 19:09 UTC

Market Talk

Oil Futures Bounce in Defiance of Downbeat Data -- Market Talk

2. Juli 2025, 19:08 UTC

Market Talk

Dollar Trims Gains as Investors Brace for Cooling Jobs Market -- Market Talk

2. Juli 2025, 19:01 UTC

Market Talk

U.S. Natural Gas Ticks Up Ahead of Storage Data -- Market Talk

2. Juli 2025, 18:08 UTC

Market Talk

Fossil Fuels Rule Energy Roost As U.S. Marks Independence -- Market Talk

2. Juli 2025, 17:06 UTC

Akquisitionen, Fusionen, Übernahmen

BCE: Maple Leafs, Raptors Rights Access Through Long-Term Agreement With Rogers, Subject to League Approvals

2. Juli 2025, 17:05 UTC

Akquisitionen, Fusionen, Übernahmen

BCE: Access to Content Rights for Toronto Maple Leafs, Toronto Raptors on TSN Secured Through 2043/2044 Season

2. Juli 2025, 17:04 UTC

Akquisitionen, Fusionen, Übernahmen

BCE: Proceeds of MLSE Stake Sale to Support Financing of Acquisition of Ziply Fiber

2. Juli 2025, 17:04 UTC

Akquisitionen, Fusionen, Übernahmen

BCE Inc. Concludes Sale of Minority Stake in Maple Leaf Sports & Entertainment

2. Juli 2025, 17:02 UTC

Akquisitionen, Fusionen, Übernahmen

Rogers Communications: Now Largest Owner With 75% Interest in Maple Leaf Sports & Entertainment

2. Juli 2025, 17:02 UTC

Akquisitionen, Fusionen, Übernahmen

Rogers Communications Closes Deal to Buy BCE's 37.5% Stake in Maple Leaf Sports & Entertainment for C$4.7B

2. Juli 2025, 16:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

2. Juli 2025, 16:20 UTC

Market Talk

Cushing Crude Stock Slide Keeps Bid in WTI -- Market Talk

2. Juli 2025, 16:20 UTC

Market Talk

Health Care Roundup: Market Talk

2. Juli 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

2. Juli 2025, 16:11 UTC

Market Talk

Copper Prices Hold Higher on Supply Disruption, Tariff Uncertainty -- Market Talk

2. Juli 2025, 16:09 UTC

Market Talk

Gold Futures Rise, Recouping Some Losses -- Market Talk

2. Juli 2025, 15:59 UTC

Ergebnisse

These Stocks Are Moving the Most Today: Tesla, Centene, Apple, Adobe, Rigetti Computing, Greenbrier, and More -- Barrons.com

2. Juli 2025, 15:17 UTC

Market Talk

Oil Market to Keep Close Watch on U.S. Payrolls -- Market Talk

2. Juli 2025, 15:08 UTC

Market Talk

Luxury Sector Should Report a Slowdown -- Market Talk

2. Juli 2025, 15:00 UTC

Akquisitionen, Fusionen, Übernahmen

Glencore: Merger of Viterra With Bunge Global Closed

Peer-Vergleich

Kursveränderung

Krystal Biotech Inc Prognose

Kursziel

By TipRanks

40.55% Vorteil

12-Monats-Prognose

Durchschnitt 195.38 USD  40.55%

Hoch 240 USD

Tief 155 USD

Basierend auf 9 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Krystal Biotech Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

9 ratings

8

Buy

1

Halten

0

Sell

Technischer Score

By Trading Central

133.221 / 169.73Unterstützung & Widerstand

Kurzfristig

Very Strong Bearish Evidence

Mittelfristig

Strong Bearish Evidence

Langfristig

Bearish Evidence

Stimmung

By Acuity

163 / 380 Ranking in Gesundheitswesen

Nachrichtenstimmung

Neutral

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Überdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Krystal Biotech Inc

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.